Lite Strategy, Inc. (LITS)
0.9758
0.00 (0.00%)
USD |
NASDAQ |
Aug 31, 16:00
0.9758
0.00 (0.00%)
After-Hours: 17:38
Lite Strategy Free Cash Flow : -110.42M for March 31, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| March 31, 2026 | -110.42M |
| December 31, 2025 | -12.16M |
| September 30, 2025 | -13.90M |
| June 30, 2025 | -20.84M |
| March 31, 2025 | -36.59M |
| December 31, 2024 | -36.25M |
| September 30, 2024 | -43.65M |
| June 30, 2024 | -50.69M |
| March 31, 2024 | -43.78M |
| December 31, 2023 | -52.98M |
| September 30, 2023 | -56.19M |
| June 30, 2023 | -52.55M |
| March 31, 2023 | -57.06M |
| December 31, 2022 | -61.99M |
| September 30, 2022 | -56.34M |
| June 30, 2022 | -49.22M |
| March 31, 2022 | -44.68M |
| December 31, 2021 | -43.26M |
| September 30, 2021 | -30.65M |
| June 30, 2021 | -32.67M |
| March 31, 2021 | 47.60M |
| December 31, 2020 | 52.17M |
| September 30, 2020 | 37.69M |
| June 30, 2020 | 33.36M |
| March 31, 2020 | -43.71M |
| Date | Value |
|---|---|
| December 31, 2019 | -44.02M |
| September 30, 2019 | -30.90M |
| June 30, 2019 | -29.64M |
| March 31, 2019 | -25.32M |
| December 31, 2018 | -20.18M |
| September 30, 2018 | -27.56M |
| June 30, 2018 | -21.30M |
| March 31, 2018 | -20.75M |
| December 31, 2017 | -12.90M |
| September 30, 2017 | -11.90M |
| June 30, 2017 | 3.435M |
| March 31, 2017 | 3.146M |
| December 31, 2016 | -2.848M |
| September 30, 2016 | -3.329M |
| June 30, 2016 | -17.86M |
| March 31, 2016 | -21.12M |
| December 31, 2015 | -24.88M |
| September 30, 2015 | -27.11M |
| June 30, 2015 | -28.08M |
| March 31, 2015 | -27.22M |
| December 31, 2014 | -24.16M |
| September 30, 2014 | -22.16M |
| June 30, 2014 | -19.50M |
| March 31, 2014 | -16.40M |
| December 31, 2013 | -13.97M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| SELLAS Life Sciences Group, Inc. | -28.42M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
| Savara, Inc. | -110.66M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -1.52M |
| Cash from Investing (Quarterly) | 2.098M |
| Cash from Financing (Quarterly) | -1.792M |
| Free Cash Flow Per Share (Quarterly) | -2.843 |
| Free Cash Flow to Equity (Quarterly) | -101.52M |
| Free Cash Flow to Firm (Quarterly) | -101.52M |
| Free Cash Flow Yield | -414.4% |